Activating mutations within the EGFR kinase domain: a molecular predictor of disease-free survival in resected pulmonary adenocarcinoma.

Young Joo Lee, In Kyu Park, Moo Suk Park, Hye Jin Choi, Byoung Chul Cho, Kyung Young Chung, Se Kyu Kim, Joon Chang, Jin Wook Moon, Hoguen Kim, Sung Ho Choi, Joo Hang Kim

Research output: Contribution to journalArticlepeer-review

70 Citations (Scopus)


PURPOSE: Although epidermal growth factor receptor (EGFR) tyrosine kinase (TK) mutations are highly predictive of response to EGFR TK inhibitors in advanced non-small-cell lung cancer (NSCLC), a prognostic value of EGFR mutations in resected NSCLC has not been established. METHODS: We retrospectively reviewed 117 patients with primary lung adenocarcinoma who underwent surgical resection between 1995 and 2005. Nucleotide sequencing of the kinase domain of EGFR (exons 18-21) was performed using nested PCR amplification of individual exons. RESULTS: Forty-eight patients (41.8%) harbored exon 19 deletion or exon 21 point mutations. EGFR mutations were more frequently found in never-smoker (P = 0.04) or in smaller-sized primary tumor (P = 0.001). A presence of EGFR mutations was significantly associated with longer disease-free survival (DFS) (20.1 vs. 34.4 months in mutated EGFR; P = 0.003). In multivariate analysis of DFS, wild-type EGFR was associated with a higher risk of recurrence, with an adjusted hazard ratio of 1.42 (95% CI, 1.1-2.41, P = 0.04), as compared to mutated EGFR. However, no significant association was observed between EGFR mutations and overall survival (P = 0.39). Isolated brain metastasis as the first recurrence after resection was found more frequently in those patients with tumors bearing EGFR mutations, although the difference was not statistically significant (9 vs. 24% in mutated EGFR, P = 0.15). CONCLUSIONS: Activating mutations within the EGFR TK domain can be used to predict the risk of recurrence in curatively resected pulmonary adenocarcinoma.

Original languageEnglish
Pages (from-to)1647-1654
Number of pages8
JournalJournal of cancer research and clinical oncology
Issue number12
Publication statusPublished - 2009 Dec

Bibliographical note

Funding Information:
Acknowledgment We thank the members of Lung Cancer Clinic Severance Hospital for thoughtful discussion and review of the manuscript. This study was supported by a faculty research grant of Yonsei University College of Medicine for 2008 (6-2008-0107).

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


Dive into the research topics of 'Activating mutations within the EGFR kinase domain: a molecular predictor of disease-free survival in resected pulmonary adenocarcinoma.'. Together they form a unique fingerprint.

Cite this